139 related articles for article (PubMed ID: 37808936)
1. Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case-control study.
González S; Olszevicki S; Gaiano A; Salazar M; Regairaz L; Varela Baino AN; Bartel E; Varela T; González Martínez VV; Pesci S; Marín L; Irassar JI; Ceriani L; Garcia E; Kreplak N; Estenssoro E; Marsico F
Lancet Reg Health Am; 2023 Nov; 27():100607. PubMed ID: 37808936
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
Rearte A; Castelli JM; Rearte R; Fuentes N; Pennini V; Pesce M; Barbeira PB; Iummato LE; Laurora M; Bartolomeu ML; Galligani G; Del Valle Juarez M; Giovacchini CM; Santoro A; Esperatti M; Tarragona S; Vizzotti C
Lancet; 2022 Mar; 399(10331):1254-1264. PubMed ID: 35303473
[TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
[TBL] [Abstract][Full Text] [Related]
4. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials.
Macchia A; Ferrante D; Bouzas MB; Angeleri P; Biscayart C; Geffner J; Mammana L; Zapiola I; López EL; Gentile A; Varese A; Mazzitelli I; García FDD; Sharff D; Lucconi V; Sujansky P; Mariani J; de Quirós FGB
Lancet Reg Health Am; 2022 May; 9():100196. PubMed ID: 35128512
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.
Pascuale CA; Varese A; Ojeda DS; Pasinovich ME; Lopez L; Rossi AH; Rodriguez PE; Miglietta EA; ; Mazzitelli I; Di Diego Garcia F; Sanchez L; Rouco SO; Gonzalez Lopez Ledesma MM; Zurano JP; Mazzitelli B; Scruzzi G; Barbero P; Cardozo D; Gallego S; Borda M; Diaz M; ; ; Ridao F; Rosales AB; ; Bhon J; Talia JM; Diangelo ME; Lacaze MA; ; Aime B; Gutierrez SI; Ercole R; Toro R; Tau L; Delaplace L; Compagnucci MF; ; Sartori C; Desimone I; Echegoyen C; Velazquez P; Testa C; ; Hozbor D; Docena G; Laino CH; Kreplak N; Pifano M; Barbas G; Rearte A; Vizzotti C; Castelli JM; Geffner J; Gamarnik AV
Cell Rep Med; 2022 Aug; 3(8):100706. PubMed ID: 35926505
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: A randomised clinical trial in an elderly population.
Kundro MA; Losso MH; Macchia A; Pastor I; Alonso Serena M; Gestoso C; Moreno Macías L; Crupi F; Acosta MC; Ivalo S; Ghioldi M; Bouzas MB; Mammana L; Zapiola I; Mazzitelli I; Varese A; Geffner J; Biscayart C; Angeleri P; Lopez E; Gentile A; Ferrante D; de Quiros FGB
Public Health Pract (Oxf); 2022 Dec; 4():100313. PubMed ID: 36090797
[TBL] [Abstract][Full Text] [Related]
9. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
Park S; Gatchalian KK; Oh H
Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
Mallah SI; Alawadhi A; Jawad J; Wasif P; Alsaffar B; Alalawi E; Mohamed AM; Butler AE; Alalawi B; Qayed D; Almahari SA; Mubarak A; Mubarak A; Saeed S; Humaidan A; Kumar N; Atkin S; Alqahtani M
Vaccine; 2023 Mar; 41(12):1925-1933. PubMed ID: 36725431
[TBL] [Abstract][Full Text] [Related]
11. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of SARS-CoV-2 infection risks after primary vaccination with BNT162b2, BBIBP-CorV, or ChAdOx1-nCOV-19 and after homologous and heterologous booster vaccinations with these vaccines and evaluation of SARS-CoV-2 reinfection profiles.
Djorwé S; Bousfiha A; Nzoyikorera N; Nyandwi J; Kawthar B; Malki A
Biomedicine (Taipei); 2023; 13(3):31-48. PubMed ID: 37937059
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study.
Castelli JM; Rearte A; Olszevicki S; Voto C; Del Valle Juarez M; Pesce M; Iovane AN; Paz M; Chaparro ME; Buyayisqui MP; Markiewicz MB; Landoni M; Giovacchini CM; Vizzotti C
BMJ; 2022 Nov; 379():e073070. PubMed ID: 36450402
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study.
González S; Olszevicki S; Gaiano A; Baino ANV; Regairaz L; Salazar M; Pesci S; Marín L; Martínez VVG; Varela T; Ceriani L; Garcia E; Kreplak N; Navarro A; Estenssoro E; Marsico F
Lancet Reg Health Am; 2022 Sep; 13():100316. PubMed ID: 35872665
[TBL] [Abstract][Full Text] [Related]
15. Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.
Eliçabe RJ; Distel MN; Jofré BL; Leporati M; Silva JE; Arias JL; Gorlino CV; Funes SC; Velazquez M; Vitale P; Davicino RC; Di Genaro MS
Vaccine; 2023 Jan; 41(2):476-485. PubMed ID: 36481109
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study.
Heidarzadeh A; Amini Moridani M; Khoshmanesh S; Kazemi S; Hajiaghabozorgi M; Karami M
Int J Infect Dis; 2023 Mar; 128():212-222. PubMed ID: 36572376
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K
Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
Monge S; Rojas-Benedicto A; Olmedo C; Mazagatos C; José Sierra M; Limia A; Martín-Merino E; Larrauri A; Hernán MA;
Lancet Infect Dis; 2022 Sep; 22(9):1313-1320. PubMed ID: 35658998
[TBL] [Abstract][Full Text] [Related]
20. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
